OncoMatch/Clinical Trials/NCT06896422
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Is NCT06896422 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Glutathione and PD1 Inhibitor for non-small cell lung cancer.
Treatment: Glutathione · PD1 Inhibitor · Chemotherapy — Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Prior therapy
Must have received: chemotherapy — first-line
Documented disease progression following first-line chemotherapy or chemo-immunotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify